1. Home
  2. ADPT vs MANE Comparison

ADPT vs MANE Comparison

Compare ADPT & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$27.73

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Veradermics Incorporated Common Stock

MANE

Veradermics Incorporated Common Stock

N/A

Current Price

$119.17

Market Cap

5.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
MANE
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
5.5B
IPO Year
2019
2026

Fundamental Metrics

Financial Performance
Metric
ADPT
MANE
Price
$27.73
$119.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$33.86
★ $187.33
AVG Volume (30 Days)
★ 2.1M
563.6K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.89
N/A
EPS
★ N/A
N/A
Revenue
★ $276,976,000.00
N/A
Revenue This Year
$10.85
N/A
Revenue Next Year
$21.60
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 54.77
N/A
52 Week Low
$12.00
$35.43
52 Week High
$32.21
$156.63

Technical Indicators

Market Signals
Indicator
ADPT
MANE
Relative Strength Index (RSI) 49.06 41.83
Support Level $24.02 $106.18
Resistance Level $29.92 $132.58
Average True Range (ATR) 1.71 8.63
MACD -0.09 -3.06
Stochastic Oscillator 31.91 1.60

Price Performance

Historical Comparison
ADPT
MANE

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About MANE Veradermics Incorporated Common Stock

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Share on Social Networks: